Advancing a Transformative Double-Stranded RNA Immunotherapy Platform for Gastrointestinal Tumors🔒 SSL Verified
Live Data Status: |E-commerce & Retail
Welcome to the detailed analysis for oncolyticsbiotech.com. This domain is officially recognized as Unleashing the power of the immune system to fight cancer | Oncolytics Biotech. According to their official web presence, their primary focus is: "Oncolytics is developing pelareorep, a unique immunotherapy with the power to awaken the immune system and unlock its antitumor potential across cancer types".
Table of Contents
- Tech Stack
- WordPressCloudflare
- Link Profile
- Internal Pages: 109Outbound Links: 11
- Localization
- en
6-Month Traffic Trend Estimate
M1
M2
M3
M4
M5
M6
Estimated Market Value
$4,218
Based on domain age, authority, and keyword relevance.
TLD Availability Risk
- oncolyticsbiotech.comTaken
- oncolyticsbiotech.netTaken
- oncolyticsbiotech.orgTaken
- oncolyticsbiotech.ioAvailable
- oncolyticsbiotech.coAvailable
- oncolyticsbiotech.aiAvailable
Content Snippets from oncolyticsbiotech.com
"We are developing pelareorep, a first-in-class double-stranded RNA (dsRNA) immunotherapeutic agent with Fast Track Designation for colorectal and pancreatic cancer, as a platform immunotherapy for the treatment of gastrointestinal (GI) tumors. We believe GI cancers are the largest unmet medical need in oncology and that pelareorep can extend survival while maintaining a favorable safety profile that has been demonstrated in over 1,300 patients."
"The unique mechanism of action behind pelareorep positions it as a platform immunotherapy for a variety of GI tumor indications."
"mPDAC impacts 500,000 patients globally1, representing a $3 billion total addressable market with a 15% compound annual growth rate (CAGR) projected through 20322. Despite its devastating impact, mPDAC remains one of the most challenging malignancies to treat."
"The current treatment landscape for mPDAC is dominated by chemotherapy, with no approved immunotherapy options available. mPDAC carries a dismal 3% five-year survival rate3, highlighting the critical unmet need for novel therapeutic approaches. While chemotherapy regimens can provide some benefit, they often come with significant side effects and limited durability of response."
Key Topics & Focus Areas for oncolyticsbiotech.com:
Pelareorep
Pipeline
News
Company
Science
Investors
By comparing oncolyticsbiotech.com to other leading websites in its niche, marketers and researchers can identify key traffic sources and growth opportunities. Explore our related resources below to find websites similar to oncolyticsbiotech.com.
Frequently Asked Questions
Is oncolyticsbiotech.com a safe and secure website?
Yes, according to our latest analysis, we detected a valid SSL certificate ensuring a secure connection.
What is the authority score of oncolyticsbiotech.com?
As of July 23, 2026, oncolyticsbiotech.com holds an estimated domain authority score of 79/100 based on our VisitRank tracking algorithms.
What are the top alternatives to oncolyticsbiotech.com?
You can find the best alternatives and similar sites to oncolyticsbiotech.com in our explore section, which includes competitors in the E-commerce & Retail sector.
Data Sources & Methodology: DNS telemetry and routing records are resolved via live root servers. Market valuation estimates are computed algorithmically based on proprietary historical indexation multiples and standardized digital asset appraisal methodologies.
Common Misspellings & Typo Domains for oncolyticsbiotech.com:
ocnolyticsbiotech.comonolyticsbiotech.comonncolyticsbiotech.comoncolyticsbiotech.comoncolytocsbiotech.comoncolyticsbootech.comoncolyticsbiotach.comobcolyticsbiotech.comohcolyticsbiotech.com